LOS ANGELES--(BUSINESS WIRE)--Glancy Binkow & Goldberg LLP announces an investigation on behalf of investors of AngioDynamics, Inc. (“AngioDynamics” or the “Company”) (NASDAQ: ANGO). The investigation concerns whether the Company and certain of its officers and/or directors possibly violated the federal securities laws. The investigation focuses on allegations that certain statements issued by the Company between October 9, 2014 and April 9, 2015 (the “Period”), regarding AngioDynamics’ business, operations and prospects were false or misleading.
AngioDynamics is a provider of minimally invasive medical devices used by professional healthcare providers for vascular access, surgery, peripheral vascular disease and oncology. The investigation relates to the Company’s announcement of its financial results for the third quarter fiscal 2015 on April 9, 2015. The Company reported a quarterly loss of $4.3 million and advised investors of a downgrade in its full year outlook by nearly 4%. On this news, the Company’s stock declined by as much as 8% on heavy volume.
If you purchased AngioDynamics shares during the Period, and have suffered any loss to your investment please contact Lesley Portnoy to discuss this matter. If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, of Glancy Binkow & Goldberg LLP, 1925 Century Park East, Suite 2100, Los Angeles, California 90067, at (310) 201-9150, by e-mail to email@example.com, or visit our website at http://www.glancylaw.com. If you inquire by email, please include your mailing address, telephone number and number of shares purchased.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.